On to the Next Level: ClinicalTrials.gov Goes (More Fully) Plain!

Authors

  • Thomas M. Schindler, PhD BioNTech SE and Lay & Regulatory Writing, Mainz and Biberach a. d. Riss, Germany

DOI:

https://doi.org/10.55752/amwa.2022.217

Abstract

It’s a rather tacit revolution that happened on September 26, 2022, in the “What’s new” section of the https://clinicaltrials.gov website. A short announcement states that “A Plain Language Checklist for Lay Brief Summaries (PDF) is added to the Support Materials under Data Element Definitions, Templates, and Checklists. The checklist identifies plain language best practices to help investigators write brief summaries that can be easily understood by the general public.”


This unemotional announcement is a tremendous move toward more understandable entries in ClinicalTrials.gov (CT.gov)—that is, a move returning to CT.gov’s original intentions.

Downloads

Published

2022-12-14

How to Cite

1.
Schindler T. On to the Next Level: ClinicalTrials.gov Goes (More Fully) Plain!. AMWA. 2022;37(4). doi:10.55752/amwa.2022.217

Issue

Vol. 37 No. 4 (2022)

Section

Topical Features

License

Copyright Notice

Authors of manuscripts accepted for publication retain copyright in their work but are required to grant to AMWA exclusive worldwide first publication rights and further grant a nonexclusive license for other uses of the manuscript for the duration of their copyright as outlined in the Agreement on Authors' Rights and Responsibilities. In the same agreement, authors are required to confirm that the material submitted for publication, both in its paper and electronic versions, including reproductions of other works (eg, photographs, maps, etc.) does not infringe upon any existing copyright.

Any reproduction within two years following the date of publication requires the permission of the Editor-in-Chief of the AMWA Journal. 

Contact managingeditor@amwa.org for all requests for reuse.